Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Takeda Pharmaceutical Co. Ltd (TAK)

Takeda Pharmaceutical Co. Ltd (TAK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 56,981,320
  • Shares Outstanding, K 3,117,140
  • Annual Sales, $ 18,875 M
  • Annual Income, $ 982,130 K
  • 60-Month Beta 0.89
  • Price/Sales 3.10
  • Price/Cash Flow 8.55
  • Price/Book 1.29

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.13
  • Growth Rate Est. (year over year) +768,361.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.00 +1.56%
on 02/24/20
20.42 -10.48%
on 02/07/20
-1.55 (-7.82%)
since 01/24/20
3-Month
18.00 +1.56%
on 02/24/20
20.80 -12.12%
on 11/27/19
-2.10 (-10.30%)
since 11/22/19
52-Week
16.10 +13.54%
on 08/27/19
21.61 -15.41%
on 03/20/19
-1.70 (-8.51%)
since 02/22/19

Most Recent Stories

More News
Takeda Demonstrates Business Momentum, Accelerated Integration Synergies, and Raises FY2019 Guidance Including Positive Reported Operating Profit

Takeda Pharmaceutical Company Limited (TOKYO:4502)(NYSE:TAK):

TKPYY : 16.5900 (-0.90%)
TAK : 18.28 (-2.71%)
Melanie Ivarsson, Ph.D. Joins Moderna as Chief Development Officer

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today...

MRNA : 18.59 (+1.97%)
TAK : 18.28 (-2.71%)
PFE : 34.67 (-2.94%)
LLY : 138.15 (-2.74%)
AZN : 47.59 (-5.14%)
MRK : 81.33 (-1.23%)
Francois Nader, M.D., Joins Moderna's Board of Directors

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today...

SHPG : 179.20 (+4.10%)
MRNA : 18.59 (+1.97%)
TAK : 18.28 (-2.71%)
SNY : 49.84 (-1.99%)
XLRN : 90.20 (-4.56%)
PRVL : 16.01 (-5.71%)
ALXN : 99.02 (-3.99%)
AAAP : 81.63 (+0.16%)
BXLT : 46.02 (-0.39%)
CMTA : 26.35 (-0.11%)
TRVN : 0.73 (-2.25%)
NOVN : 0.52 (-5.15%)
AZN : 47.59 (-5.14%)
MRK : 81.33 (-1.23%)
Halozyme (HALO) Earnings & Revenues Miss Estimates in Q3

Halozyme (HALO) reports lower-than-expected earnings and revenues in third-quarter 2019. It lowers the sales outlook for 2019 and raises the same for operating expenses.

JNJ : 145.91 (-2.68%)
RHHBY : 42.5400 (-3.38%)
HALO : 21.43 (-1.83%)
TAK : 18.28 (-2.71%)
4 Biotech Stocks That Could Keep Beating Wall Street

The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.

BMY : 63.97 (-2.53%)
LLY : 138.15 (-2.74%)
ACAD : 42.25 (-6.38%)
CHRS : 21.68 (-3.77%)
CELG : 108.24 (+0.10%)
BIIB : 325.98 (-3.19%)
INCY : 78.87 (-2.50%)
ADPT : 30.83 (-9.75%)
ALEC : 27.35 (-10.24%)
NGM : 18.87 (+16.55%)
TAK : 18.28 (-2.71%)
Takeda Reports Solid Second Quarter FY2019 Results and Raises Profit Guidance for the Full Year

Takeda Pharmaceutical Company Limited (TOKYO:4502)(NYSE:TAK):

TKPYY : 16.5900 (-0.90%)
TAK : 18.28 (-2.71%)
Seattle Genetics (SGEN) Q3 Loss Widens, Revenues Top Mark

Seattle Genetics (SGEN) incurs wider-than-expected loss in third-quarter 2019 but rides high on revenue beat.

RHHBY : 42.5400 (-3.38%)
MRK : 81.33 (-1.23%)
SGEN : 116.00 (-0.85%)
TAK : 18.28 (-2.71%)
Easy Investing Secrets to an Early Retirement - October 11, 2019

Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments,...

TAK : 18.28 (-2.71%)
UGI : 40.57 (-1.72%)
T : 38.05 (-1.30%)
Signs That Your Trading Will Ruin Your Retirement - October 09, 2019

From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.

GLPI : 48.76 (-3.06%)
FMNB : 15.90 (-0.93%)
TAK : 18.28 (-2.71%)
Karyopharm Signs $150M Royalty Agreement to Support Xpovio

Karyopharm (KPTI) signs royalty agreement with HealthCare Royalty Partners for up to $150 million to fund Xpovio's commercialization and development.

JNJ : 145.91 (-2.68%)
CELG : 108.24 (+0.10%)
KPTI : 14.79 (-8.08%)
TAK : 18.28 (-2.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Average short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade TAK with:

Business Summary

Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide...

See More

Key Turning Points

2nd Resistance Point 18.60
1st Resistance Point 18.44
Last Price 18.28
1st Support Level 18.06
2nd Support Level 17.84

See More

52-Week High 21.61
Fibonacci 61.8% 19.51
Fibonacci 50% 18.85
Last Price 18.28
Fibonacci 38.2% 18.20
52-Week Low 16.10

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar